Article Data

  • Views 395
  • Dowloads 123

Original Research

Open Access

The clinicopathologic significance of the ARID1A expression in ovarian epithelial tumors

  • D. Ayaz1
  • G. Diniz3,*,
  • S. Sayhan1
  • D.S. Kahraman1
  • T. Karadeniz1
  • M. Sanci2

1Pathology Department, Izmir Tepecik Education and Research Hospital, Izmir, Turkey

2Gynecological Oncology Clinics, Izmir Tepecik Education and Research Hospital, Izmir, Turkey

3Pathology Department, Izmir Democracy University, Izmir, Turkey

DOI: 10.12892/ejgo4467.2019 Vol.40,Issue 4,August 2019 pp.567-571

Accepted: 06 November 2017

Published: 10 August 2019

*Corresponding Author(s): G. Diniz E-mail:


Objective: AT-rich interactive domain 1A (ARID1A) or BAF250a protein, which is encoded by tumor suppressor ARID1A gene, is involved in chromatin remodeling. The aim of this study is to investigate the association between tissue ARID1A expression and ovarian epithelial tumors. Material and Methods: ARID1A expression was studied in a total of 137 formalin-fixed, paraffin-embedded specimens of ovarian epithelial tumors. Results: Statistically, normal ARID1A expression was determined in borderline and malignant serous tumors (p < 0.001). On the contrary, the decreased levels of ARID1A expression were found in endometrioid and mucinous carcinomas, as well as in benign serous tumors (0.033). Conclusions: This study demonstrated the presence of a relationship between ARID1A expression deficiency and pathogenesis of mucinous and endometrioid carcinomas. Contrary to previous studies, ARID1A expression was normal in borderline serous tumors similar to serous carcinomas. Based on these results, it can be suggested that pathogenesis of borderline serous ovarian tumors is closer to high-grade than to low-grade serous carcinomas.


Ovary, ARID1A; Serous tumors; Mucinous tumors; Endometrioid tumors

Cite and Share

D. Ayaz,G. Diniz,S. Sayhan,D.S. Kahraman,T. Karadeniz,M. Sanci. The clinicopathologic significance of the ARID1A expression in ovarian epithelial tumors. European Journal of Gynaecological Oncology. 2019. 40(4);567-571.


[1] Kurman R.J., Ellenson L.H., Ronnett B.M.: “Bleustein’s Pathology of the Female Genital Tract”. 6th ed. New York: Springer 2011, 679.

[2] Zhu Y.F., He L.S., Zhang Z.D., Huang Q.S.: “Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas”. Asian Pac. J. Trop. Med., 2012, 5, 925.

[3] Sayhan S., Diniz G., Karadeniz T., Ayaz D., Kahraman D.S., Gokcu M., et al.: “Expression of caveolin-1 in peritumoral stroma is associated with histological grade in ovarian serous tumors. Ginekol Pol 2015;86(6):424-8.

[4] Koshiyama M., Matsumura N., Konishi I.: “Recent concepts of ovarian carcinogenesis: type I and type II”. Biomed. Res. Int., 2014, 2014, 934261.

[5] Shih IeM., Kurman R.J.: “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis”. Am. J. Pathol., 2004, 164, 1511.

[6] Landen C.N., Birrer M.J., Sood A.K.: “Early events in the pathogenesis of epithelial ovarian cancer”. J. Clin. Oncol., 2008, 26, 995.

[7] Patsialou A., Wilsker D., Moran E.: “DNA-binding properties of ARID family proteins”. Nucleic Acids Res., 2005, 33, 66.

[8] Huang J., Zhao Y.L., Li Y., Fletcher J.A., Xiao S.: “Genomic and functional evidence for an ARID1A tumor suppressor role”. Genes Chromosomes Cancer, 2007, 46, 745.

[9] Wang X., Nagl N.G., Flowers S., Zweitzig D., Dallas P.B., Moran E.: “Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors”. Int. J. Cancer, 2004, 112, 636.

[10] Samartzis E.P., Gutsche K., Dedes K.J., Fink D., Stucki M., Imesch P.: “Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition”. Oncotarget, 2014, 5, 5295.

[11] Ayhan A., Mao T.L., Seckin T., Wu C.H., Guan B., Ogawa H., et al.: “Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma”. Int. J. Gynecol. Cancer, 2012, 22, 1310.

[12] Solakoglu Kahraman D., Diniz G., Sayhan S., Ayaz D., Uncel M., Karadeniz T., et al.: “Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix”. APMIS, 2015, 123, 847.

[13] Takeda T., Banno K., Okawa R., Yanokura M., Iijima M., Irie-Kunitomi H., et al.: “ARID1A gene mutation in ovarian and endometrial cancers”. Oncol. Rep., 2016, 35, 607.

[14] Shih IeM., Kurman R.J.: “Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges”. Clin. Cancer Res., 2005, 11, 7273.

[15] Wu C.H., Mao T.L., Vang R., Ayhan A., Wang T.L., Kurman R.J., et al.: “Endocervicaltype mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A”. Int. J. Gynecol. Pathol., 2012, 31, 297.

[16] Guan B., Mao T.L., Panuganti P.K., Kuhn E., Kurman R.J., Maeda D., et al.: “Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma”. Am. J. Surg. Pathol., 2011, 35, 625.

[17] Werner H.M., Berg A., Wik E., Birkeland E., Krakstad C., Kusonmano K., et al.: “ARID1A loss is prevalent in endometrial hyper- plasia with atypia and low-grade endometrioid carcinomas”. Mod. Pathol., 2013, 26, 428.

[18] Cho H., Kim J.S., Chung H., Perry C., Lee H., Kim J.H.: “Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer”. Hum. Pathol., 2013, 44, 1365.

[19] Yokoyama Y., Matsushita Y., Shigeto T., Futagami M., Mizunuma H.: “Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer”. J. Gynecol. Oncol., 2014, 25, 58.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time